Cardiome Pharma Corp.

21.11.2013 – 13:47
Europace Publishes Data Supporting Use of BRINAVESS(TM) (Vernakalant) as a First Line Agent for Pharmacological Cardioversion of Atrial Fibrillation
Vancouver, British Columbia (ots/PRNewswire) - NASDAQ: CRME TSX: COM Cardiome Pharma Corp. today announced that a publication titled, Pharmacological Cardioversion of Atrial Fibrillation with Vernakalant: Evidence in Support of the ESC Guidelines, was published in Europace, the official Journal of the European Heart ...
mehr
18.11.2013 – 22:20
Cardiome to Acquire Correvio LLC
Vancouver, British Columbia And Geneva (ots/PRNewswire) - - Company to host webcast and conference call today at 5:00 p.m. EST - NASDAQ: CRME TSX: COM Cardiome Pharma Corp. today announced that it has completed the acquisition of Correvio LLC ("Correvio"), a privately held pharmaceutical company headquartered in Geneva, Switzerland. Key benefits of the transaction include the following: - Accelerates Cardiome's launch of BRINAVESS(TM) (vernakalant IV) and its transformation ...
mehr